On November 10, 2026 (announced November 11), IASO Bio announced that the Investigational New Drug (IND) application for IASO208, a CD20-targeting in vivo CAR-T therapy developed on its proprietary InTelliCAR platform, was approved by China’s National Medical Products Administration (NMPA), following the U.S. FDA’s implicit clearance in September 2026. As the first lentiviral-vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will build on Chinese investigator-initiated trial (IIT) data to initiate a Phase Ib study directly in the United States for adults with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The China IND approval marks the formal entry of the InTelliCAR platform into synchronized U.S.–China clinical development and validates leveraging China’s early clinical data to support global registrational development. IASO208 is the company’s first product to obtain IND approval through China’s 30-day expedited review pathway, demonstrating mature end-to-end capabilities across CMC, nonclinical studies, clinical trial design and ...
On November 13, 2026, Rezolute (Nasdaq: RZLT) announced positive results from the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism (tumor HI), with the primary efficacy endpoint achieved based on preliminary results from a November 5 data evaluation; full topline results for the completed study, including statistical analysis, are expected by mid-December 2026. The primary endpoint is the proportion of patients achieving at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency. Statistical significance requires the lower bound of the 95% confidence interval to exceed 30%, equating to at least 9 responders (≥56%) among 16 participants. To date, 13 participants have met the responder criterion, including 12 who completely discontinued IV glucose; one participant who entered hospice and died of cancer progression is classified as a non-responder. The 16 enrolled participants comprise four with non-islet cell tumors and 12 with ...
Recently, U.S. biopharmaceutical company Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection in the Southern District of Texas Bankruptcy Court. The company has reportedly signed a restructuring support agreement with creditors and plans to merge with Ayrmid through a court-supervised sale process. Ayrmid will be the lead bidder, and the transaction is expected to close in the first quarter of 2027, subject to court approval and permission for other parties to submit competitive offers. On the day the news broke, Karyopharm’s stock price plummeted 83% , closing at $0.11, leaving its market capitalization at only about $2.5 million; at the beginning of the year, its stock price was above $7, meaning the cumulative decline this year is close to 99% . Why has Biotech, a company that once had the world’s first nuclear export protein (XPO1) inhibitor and annual sales of over $100 million, come to the brink of bankruptcy? ...
Why hasn’t the highly anticipated bispecific antibody, Akeso and Summit, received FDA approval? How far are Chinese innovative drugs from going global? On November 15, 2026, the U.S. FDA announced that its initial application for marketing approval in the United States for ivonescimab, an anticancer drug developed by China’s Akeso Biopharma and partially commercialized in overseas markets by Summit Therapeutics in the United States, was rejected. The FDA issued a Complete Response Letter (CRL), stating that the existing data was insufficient to support approval, and the applicant company could submit supplementary evidence and reapply. The reason can be summarized as follows: the FDA believed that the improvement in progression-free survival (PFS) was insufficient to compensate for the uncertainty in overall survival (OS) evidence, and that the overall benefit could not be confirmed to outweigh the risks. While the drug demonstrated the ability to delay cancer progression, it failed to sufficiently ...
On November 13, the official website of the National Medical Products Administration (NMPA) showed that the marketing application of the generic drug Chidamide tablets submitted by Nanjing Chia Tai Tianqing Pharmaceutical was approved, making it the first company in China to obtain approval for the generic version of this drug. Chidamide is a domestically developed Class 1.1 new drug independently developed by Shenzhen Chipscreen Biosciences and approved for marketing in 2014. In recent years, with the expansion of indications and coverage by medical insurance, the market size of this drug has continued to grow. In 2025, its sales in domestic hospitals reached 595 million yuan, making it an anti-tumor drug with a market size of nearly 600 million yuan. Nanjing Chia Tai Tianqing Pharmaceutical Group has become the first company in China to obtain approval for the production and marketing of generic versions of Chidamide tablets, officially obtaining the qualification ...
On November 14, Conba announced that Adneuris Therapeutics, which holds overseas rights to cebranopadol, had submitted a New Drug Application to the US FDA for moderate to severe acute pain in adults. Cebranopadol is an investigational oral analgesic that acts on both NOP and mu-opioid receptors. The filing draws on two pivotal Phase III trials, ALLEVIATE-1 and ALLEVIATE-2, which studied acute pain after abdominoplasty and bunionectomy, respectively. Conba said both trials met their primary efficacy endpoints, with lower pain intensity and less use of rescue analgesics than placebo. Neither trial reported serious adverse events related to the study drug. The filing also includes data from a human abuse potential study. On July 3, 2026, two Conba subsidiaries signed an agreement with Adneuris for development and commercialization rights in Greater China, with an upfront payment, milestone payments and royalties. Adneuris expects the FDA to communicate its filing decision within approximately 60 ...
On November 16, SSY Group (02005) announced that it had renewed reimbursement coverage for stiripentol powder for oral suspension. The product remains on China’s 2026 National Reimbursement Drug List. The product was approved in 2023 as China’s first generic stiripentol and comes in 250 mg and 500 mg strengths. It is used primarily to treat Dravet syndrome, also known as severe myoclonic epilepsy of infancy. China included the syndrome in its first rare disease list in 2018. Source: http://finance.eastmoney.com/a/202611163931669467.html
Drugdu.com expert’s respons When engaging in foreign trade of pharmaceuticals and medical devices, some overseas buyers will mention in their inquiries that they already have suppliers they have worked with for many years, and they only hope to learn about other manufacturers. For suppliers, this type of inquiry can sometimes be confusing. Since the buyer already has a stable procurement channel, why are they still looking for new manufacturers? Are they just trying to get a quote to pressure their existing supplier into lowering prices? If there are no short-term procurement plans, is it still necessary to invest time in follow-up? This scenario is quite common in pharmaceutical procurement. Many overseas pharmaceutical factories, medical device distributors and large importers will regularly look for new supply sources even when their current suppliers are performing well. Enterprises aim to maintain the stability of their procurement channels while avoiding over-reliance on a single ...
recently announced that the National Medical Products Administration (NMPA) of China has formally accepted its marketing application for Shingrix (recombinant herpes zoster vaccine [CHO cell], abbreviated as RZV) pre-filled syringe (PFS) formulation, which is used to prevent shingles. The active ingredient in the pre-filled syringe formulation is completely identical to that of the existing lyophilized formulation (lyophilized antigen + liquid adjuvant), simplifying the vaccination preparation process for medical personnel by eliminating the need for reconstitution of the lyophilized antigen before use. A GSK press release stated that during the 9th China International Import Expo, it showcased the latest progress in the deployment of its innovative vaccines and drugs in China, with Shingrix, the shingles vaccine that continues to expand its beneficiary population, being one of the highlights of its booth. Following approval for expanded indications in China, Shingrix has achieved new progress in dosage form innovation. GSK’s pre-filled syringe formulation ...
On November 10, the CDE website showed that Novo Nordisk’s (Novo Nordisk) marketing application for the Class 1 new drug, camrelintide smegglutide injection, for long-term weight management, was accepted. CagriSema is an investigational fixed-dose combination therapy consisting of the long-acting amylintide receptor agonist and the GLP-1 receptor agonist semagglutide, administered subcutaneously once weekly. The two components work synergistically through different and complementary mechanisms of action on pathways related to appetite and weight regulation. In December 2025, Novo Nordisk submitted a New Drug Application to the FDA for CagriSema, which is designed to help obese or overweight adult patients lose weight and maintain the weight loss effect in the long term, especially for patients with at least one weight-related comorbidity, in conjunction with a low-calorie diet and increased physical activity. Novo Nordisk stated that, if approved, CagriSema will be the first injectable combination of a GLP-1 receptor agonist and an amylin ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.